NanoString Technologies has secured an option to an exclusive worldwide licence for a 186-gene signature that could determine the prognosis of patients diagnosed with hepatocellular carcinoma (HCC), the most common type of liver cancer, or hepatitis C-related ...
[Published Pharmaceutical Technology - Apr 18 2013]